Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Results from pre-treatment SCC antigen assay were assessed in 106 patients with epidermoid carcinoma of the upper aerodigestive ways. The control population consisted of healthy blood donors (N = 61). Blood antigen levels ranged 1.6 ng/ml to 21.5 ng/ml in the patient population. 35 patients in 106 (i.e., 33% of cases) had levels considered pathological (greater than 2.00 ng/ml). Antigen levels were higher with increasing tumor size and when adenopathy was more marked (N+, N+R+). However, no correlation could be found with the T (stage)--N (histological) classification of tumors or with the site of lesion. Tumor immunologic response was obviously not uniform. Although the SCC antigen presents no diagnostic value, it appears to bear some prognostic significance, regardless of the tumoral stage. Antigen levels below 2.00 ng/ml correlate with (p less than 0.001) good immediate therapeutical results. On the other hand, serum levels greater than 2.00 ng/ml correlate either with non-sterilization, or with locoregional recurrence and/or rapid development of metastases. Other studies are required to confirm these data, and to demonstrate the value of long-term SCC antigen monitoring in these patients.
 ...
PMID:[Pre-treatment serum levels of SCC antigen in epidermoid carcinoma of the upper respiratory and digestive tract]. 217 39

Squamous cell carcinoma (SCC) antigen is a tumor-associated antigen isolated from the squamous cell carcinoma of the uterine cervix. In order to estimate the usefulness of the SCC antigen in monitoring the clinical behaviors of oral squamous cell carcinomas, we analyzed clinicopathologically and immunohistochemically 54 cases of squamous cell carcinoma of the oral cavity. Elevated serum SCC antigen levels were detected in 23 (42.6%) out of 54 oral squamous cell carcinomas. The positive rate of serum SCC antigen levels was significantly higher in the patients with advanced clinical stages and poorly differentiated carcinoma. The serum levels declined rapidly after the surgical operation. It is considered that the serum SCC antigen levels could be useful in monitoring the extension, effectiveness of therapy, recurrence and metastases of the oral squamous cell carcinomas. Immunohistochemically, strong staining was seen in the cytoplasm of the well-differentiated carcinoma cells.
 ...
PMID:Squamous cell carcinoma antigen in oral squamous cell carcinomas. 222 83

SCC antigen was measured in the serum of 214 patients with benign diseases and in 251 patients with various cancers. With 2.5 micrograms/L as the upper normal limit for serum, values were positive in 2.9% of 69 healthy subjects (I), 29.0% of 214 patients with benign pathologies (II), and 41% of 217 patients with active cancer (III). The highest values in group II were for patients in renal failure (64%) or with lung diseases (40%) or head-and-neck diseases (21.2%). Specificity of SCC increased (91.1%) when we excluded patients in renal failure or with creatinine values greater than 133 mumol/L. In group III, SCC values were abnormal in 57.7% of patients with squamous cell carcinoma, but in only 9.3% of those with other histological types (P less than 0.001). In squamous cell carcinoma of the lung, cervix, or head and neck, SCC values were related to tumor stage, values being highest in patients with metastases.
 ...
PMID:SCC antigen measured in malignant and nonmalignant diseases. 230 69

The SCC antigen, a tumour marker for squamous cell carcinoma, is already used for the diagnosis and follow-up of carcinoma of the cervix and the lungs. We determined the SCC antigen levels at the time of diagnosis and during therapy in 108 subjects with a squamous cell carcinoma of the head and neck. According to our results and those of other authors, the normal serum range of SCC lies between 0 and 2 ng/ml. Before therapy we found an increased titre in 38.9% of the subjects, being 6.2%, 30.8%, 47.2% and 76.2% for stages T1 to T4 respectively. Thus even some stage T3 and T4 tumours did not express the antigen. No correlation was found between the titre at the time of diagnosis and the grade of differentiation, the site of the tumour, the presence of lymph node or remote metastases, and the sex of the patient. After operation the titres returned to normal within 1 week, but after radiation or chemotherapy the titre decreased more slowly. In recurrent tumours we found a rising titre, which could be measured in several cases some weeks before the recurrence was visible. In the light of the costs and the yield of the method, we suggest determining the serum SCC antigen level once before therapy. If it is increased, subsequent estimates should be done during the succeeding years to allow early diagnosis of a recurrence of the tumour.
 ...
PMID:[Relevance of the new tumor marker SCC (squamous cell carcinoma antigen) for the diagnosis and follow-up control of squamous epithelial carcinoma of the head and neck]. 258 67

The significance of serum SCC antigen as a tumor marker was investigated in 94 women with squamous cell carcinoma of the vulva. The incidence of elevated serum SCC levels varied from 10% in FIGO stage I to 40% in FIGO stage IV. We did not observe a correlation between elevated pretreatment SCC values and the presence of lymph node metastases. During follow-up, elevated serum SCC values were observed in 8 of 19 patients (42%) with recurrent or progressive disease. It is concluded that the determination of serum SCC levels does not provide additional information in the staging of squamous cell vulvar carcinoma, but can be useful for the early detection of recurrent disease during follow-up in some patients. However, elevated serum SCC levels were also found in 25% of patients without demonstrable tumor activity during follow-up and benign skin disorders were recognized as a cause of false-positive SCC results.
 ...
PMID:Significance of serum SCC antigen as a tumor marker in patients with squamous cell carcinoma of the vulva. 280 15

Squamous cell carcinoma (SCC) antigen levels in sera and several tissues were estimated in patients with oral and maxillary cancer. The normal value of serum SCC antigen level was 1.7 ng/ml in this experiment, and 43.3% of squamous cell carcinoma was positively higher than 1.7 ng/ml as a whole, including cases of carcinoma in situ and of recurrence and metastasis in the oral region. In relation to the clinical staging of tumors, 20.0% in stage I, 14.3% in stage II, 42.9% in stage III, and 77.8% in stage IV were positive for SCC antigen. In the group with definite regional lymph node metastases, 80% of patients revealed a higher value than the normal cut-off value. Patients with recurrent SCC demonstrated elevated SCC antigen values in sera except 1 case with an early condition of recurrence. Serum SCC antigen also presented good responses to various cancer treatments. The measurement of SCC antigen does not appear to be useful for the detection of early stage oral and maxillary SCC; however, for detection of recurrence and for lymphatic and/or remote metastases in the follow-up period, it would appear that SCC antigen level would be some value.
 ...
PMID:Squamous cell carcinoma antigen in the serum of oromaxillary cancer. 312 92

Twenty-one patients with documented squamous cell carcinoma (SCC) of the anal canal underwent prospective serial collection of 101 serum samples for radioimmunoassay of SCC antigen to evaluate regression or progression of disease. Eighteen presented with primary SCC of the anal canal, two with metastatic disease, and one with a recurrence in the perineum. Median follow-up was 18 months. Thirteen of 22 serum samples were true-positives, and nine of 22 were false-negatives. Four of 79 serum samples were false-positives and 75 of 79 were true-negatives. The sensitivity of this test is 59% and the specificity is 95%, with the accuracy of a positive test being 76%.
 ...
PMID:Squamous cell carcinoma antigen as a marker for squamous cell carcinoma of the anal canal. 336 86

SCC antigen (Ag) is a tumor-associated Ag (TAA) obtained from squamous cell carcinoma of the uterine cervix. This study reports the evaluation of this TAA in patients with head and neck malignant diseases and its possible prognostic value. Serum samples from 28 patients with benign head and neck diseases from 399 patients with cancer were obtained prior to treatment. SCC Ag serum levels were determined by radioimmunoassay using 2.5 ng/ml as the upper limit of normality. Elevated SCC Ag serum levels were found in 14% of 28 patients with benign diseases, in 29% of 217 patients with primary tumors, in 48% of 46 patients with recurrence (43% in locoregional, 64% in metastases) and in 4% of 136 patients with no evidence of disease. In patients with primary tumors, SCC Ag serum levels were related to nodal involvement and tumor location with significantly higher levels in node-positive patients (p = 0.001) and in tumors located in the nasopharynx and piriform sinus (p = 0.02). Presurgical SCC Ag serum levels in patients with primary tumors had prognostic value with shorter disease-free survival in those patients with abnormal values of this TAA (p < 0.001), in both, node-negative and node-positive patients (p < 0.01). Multivariate analyses showed that SCC Ag is a significant independent predictor of disease-free survival even when other prognostic factors are considered. In conclusion, pretreatment SCC Ag serum levels are an independent prognostic indicator in patients with head and neck malignancies.
 ...
PMID:Prognostic significance of SCC antigen in the serum of patients with head and neck cancer. 865 17

A review is given of the clinical use and interpretation of serum tumor marker levels during the treatment of patients with cancer of the uterine cervix. Pretreatment serum squamous cell carcinoma (SCC) antigen provides a new prognostic factor in early stage squamous cell carcinoma of the uterine cervix. Elevated serum values of SCC antigen at the time of diagnosis of stage IB and IIA cervical cancer indicate a 3 x increased risk of tumor recurrence, independent of tumor diameter, grade or the presence of lymph node metastases. High pretreatment SCC antigen levels could therefore be used to select 'high-risk' patients for adjuvant therapy. Measurement of the serum SCC antigen levels provides a means of monitoring the effect of therapy. During the postoperative follow-up of patients with localized cancer of the uterine cervix the measurement of SCC antigen can lead to the early detection of recurrent disease when curative therapy is still an option. The profile of serum SCC antigen parallels the response to radiotherapy and provides a way of evaluating the effectiveness of chemotherapy. Serial measurements after surgery and during radio- and chemotherapy demonstrate that SCC antigen is a more sensitive marker for recognizing tumor progression or recurrence than CYFRA-21.1, TPS or CEA. When following up patients with a pure adenocarcinoma of the cervix measurements of serum CA 125 and CEA are preferred over SCC antigen measurements.
 ...
PMID:The clinical value of squamous cell carcinoma antigen in cancer of the uterine cervix. 981 80

With recent development in molecular biology, reverse transcriptase polymerase chain reaction (RT-PCR) has been applied to detect occult lymph node metastasis, but there have been few reports concerning oesophageal cancer. The objective of this study is to investigate the usefulness of the squamous cell carcinoma (SCC) antigen gene as a marker with RT-nested PCR to detect occult lymph node metastases of oesophageal cancer. The SCC antigen has been widely used as a serum tumour marker and was reported as a target gene to detect tumour cells in peripheral blood in cervical cancer. In this study, 620 lymph nodes from 14 oesophageal cancer patients were analysed. The results of RT-nested PCR were compared with that of pathological and immunohistochemical examinations. In the test of sensitivity, the RT-nested PCR detected 10(1) of SCC antigen producing cells in 10(7) peripheral blood mononucleocytes and was not found in 43 control lymph nodes. The pathological examination, immunohistochemical examination and the RT-nested PCR detected 36, 45 and 65 nodes respectively. The RT-nested PCR detected statistically more lymph nodes than the pathological or immunohistochemical examination. The sensitivity and specificity seem higher in squamous cell carcinoma cases. The SCC antigen gene is one of the more useful markers for RT-nested PCR to detect occult lymph node metastases of oesophageal cancer.
 ...
PMID:Detection of lymph node metastasis of oesophageal cancer by RT-nested PCR for SCC antigen gene mRNA. 1064


1 2 Next >>